G2TT
来源类型Report
规范类型报告
DOIhttps://doi.org/10.7249/RRA328-1
来源IDRR-A328-1
Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships
Andrew W. Mulcahy; Vishnupriya Kareddy
发表日期2021-10-27
出版年2021
页码49
语种英语
结论
  • Financial incentives drive the structure of prescription drug supply chains and the behavior of stakeholders.
  • Approximately 80 percent of spending but only 10 percent of prescriptions are for brand-name drugs. The remaining 20 percent of spending and 90 percent of prescriptions are primarily from generic drugs.
  • Manufacturing includes sourcing of active pharmaceutical ingredients, formulation, and packaging.
  • The next step is distribution. Three distributors—AmerisourceBergen, Cardinal Health, and McKesson—account for nearly all the U.S. market. Customers include large pharmacy chains, independent pharmacies, physician offices, and hospital systems.
  • Pharmacies have substantial leeway in setting retail prices. Pharmacies receive payments from pharmacy benefit managers (PBMs) and patients. PBMs assemble networks of pharmacies that agree to the PBM's payment terms in exchange for an increase in prescription volume from PBM patients.
  • The three largest PBMs—Express Scripts, CVS/Caremark, and OptumRx—cover three-fourths of U.S. prescription claims.
  • Payments for prescriptions covered by insurance involve four components. (1) Patients pay some of the cost at the point of dispensing. (2) The PBM pays the pharmacy the balance of the amount owed, as determined by their contract. (3) Discounts negotiated between the market authorization holder (the authorized seller of the drug) and PBMs are paid as rebates from the market authorization holder to PBMs. (4) PBMs are reimbursed for their payments to pharmacies and pass most or all of the rebates to payers (health insurers, large employers, or government programs), resulting in net prices to payers that are often lower than the amounts paid to pharmacies.
摘要

The authors describe the stakeholders involved in prescription drug supply chains and the flows of products, payments, and information between stakeholders. Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient's source of prescription drug coverage. Although the authors present a typical supply chain for retail pharmacy drugs, they also highlight the important supply chain distinctions for specific distribution channels and for specific types of drugs. Disparate sources exist describing each component of the supply chain, but, to the authors' knowledge, this report is the first to compile them to facilitate understanding of their interdependence and complexity.

,

The typical stakeholders, relationships, and financial incentives in prescription drug supply chains vary depending on the characteristics of a drug and how it reaches patients. Even within a specific type of drug and a particular distribution channel, differences in business practices complicate a universal description of drug supply chains. There are four common core components of drug supply chains: manufacturing, distribution, coverage and payment, and prescribing and demand.

,

Although prescription drugs are generally available to dispense when prescribed in the United States, there are important exceptions that warrant further investigation. The ability of policymakers to identify, assess, and respond to shortages and disruptions in supply chains is hampered by incomplete data.

目录
  • Chapter One

    Introduction and Approach

  • Chapter Two

    Retail Pharmacy Supply Chain Stakeholders and Relationships

  • Chapter Three

    Outpatient Facility, Inpatient Hospital, and Physician Office Supply Chains

  • Chapter Four

    Discussion and Conclusion

  • Appendix

    Pricing Term Glossary

主题Health Care Costs ; Health Care Payment Approaches ; Medicaid ; Pharmaceutical Drugs ; United States
URLhttps://www.rand.org/pubs/research_reports/RRA328-1.html
来源智库RAND Corporation (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/524607
推荐引用方式
GB/T 7714
Andrew W. Mulcahy,Vishnupriya Kareddy. Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships. 2021.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
RAND_RRA328-1.pdf(515KB)智库出版物 限制开放CC BY-NC-SA浏览
x1635338191976.jpg.p(1KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Andrew W. Mulcahy]的文章
[Vishnupriya Kareddy]的文章
百度学术
百度学术中相似的文章
[Andrew W. Mulcahy]的文章
[Vishnupriya Kareddy]的文章
必应学术
必应学术中相似的文章
[Andrew W. Mulcahy]的文章
[Vishnupriya Kareddy]的文章
相关权益政策
暂无数据
收藏/分享
文件名: RAND_RRA328-1.pdf
格式: Adobe PDF
文件名: x1635338191976.jpg.pagespeed.ic.MQYnq8cLaa.jpg
格式: JPEG

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。